Abstract 4701
Background
Cabozantinib demonstrated increased efficacy over everolimus in patients with mRCC progressing on VEGF targeted therapy in the randomised phase III METEOR trial. We report real world experience with Cabozantinib in 7 centres across the UK.
Methods
In this retrospective study, patients who started Cabozantinib from September 2016 to September 2017 within the UK EAP were included. Patients had mRCC progressing after at least 1 prior systemic treatment, PS 0-2 and adequate organ function. The goal was to analyse toxicities, efficacy and access to other drugs after progression. Adverse events (AEs) were graded using the NCI CTCAE v.4.0.3. Survival times were calculated from the start of Cabozantinib using a Kaplan-Meier model. Radiological response was assessed locally by RECIST 1.1.
Results
128 patients were included. Median follow-up was 10.5 months. Median age was 62 years, 84% had clear cell histology, and 49% were classified as intermediate risk by IMDC score. 87% had visceral M1 and 52% bone M1. Patients received a median of 2 previous lines (1-6) of therapy. Cabozantinib was used as 2nd line, 3rd line and 4th line or beyond in 56 (44%), 38 (30%) and 34 (26%) patients respectively. Baseline characteristics are summarized in the table. 48 (37%) of the patients developed G3/4 AEs, mainly fatigue (N = 14, 11%), diarrhoea (N = 12, 9%), mucositis (N = 7, 5%) and hand-foot syndrome (N = 6, 5%). No treatment-related deaths were seen. 71 patients (55%) required dose reductions. 12 (15%) discontinued Cabozantinib due to toxicity. Median OS was 9.1 months (95% CI 6.6-11.6), being 14.3 vs 9.3 vs 6.0 months for good, intermediate and poor prognostic patients, respectively (p 0.01). Median PFS was 7.7 months (95% CI 5.3-10.1). Partial response to Cabozantinib was 26%, stable disease 24%, Progressive disease 30% and was not evaluated in 20%. Only 21/81 patients (26%) stopping Cabozantinib started on subsequent treatment.Table: 893P
| Baseline characteristic | Number (%) | |
|---|---|---|
| Gender | Male Female | 87 (68) 41 (32) |
| Age | Median (range) | 62 (11-83) |
| PS ECOG | 0 1 2 | 20 (16) 85 (66) 23 (18) |
| Histology | Clear Cell Papillary Other | 107 (84) 13 (10) 8 (6) |
| IMDC Risc Category | Good Intermediate Poor Unknown | 35 (27) 62 (49) 27 (21) 4 (3) |
| Nephrectomy | Yes No | 93 (73) 35 (27) |
| Number of metastatic sites | 1 2 ≥3 | 17 (13) 46 (36) 64 (50) |
| Metastatic sites | Lung Lymph node Bone Liver Brain Pleura/Peritoneal Other | 92 (72) 55 (43) 66 (52) 42 (33) 14 (11) 19 (15) 47 (37) |
| Visceral and bone M1 spread | All patients with visceral M1 Both Visceral + bone M1 Visceral M1 without bone M1 | 110 (87) 55 (43) 54 (42) |
| Previous lines of therapy | 1 2 ≥3 | 56 (44) 38 (30) 34 (26) |
| Duration of 1st VEGFR TKI | ≤6 months >6 months | 34 (27) 94 (73) |
| 1st subsequent treatment (N = 21) | Nivolumab Axitinib Everolimus Others | 15 (71) 3 (14) 1 (5) 2 (10) |
| PD-1/PDL1 inhibitors prior to Cabo | Nivolumab PD1/PDL1-VEGF combo | 27 (21) 10 (8) |
Conclusions
Cabozantinib was safe and active in pretreated patients with mRCC.
Clinical trial identification
Legal entity responsible for the study
Alfonso Gomez de Liano.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
S. Symeonides: Research funding: Merck Sharp & Dohme. T. Powles: Advisory role and research funding: Roche, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract